This week, we are spotlighting MeMed, whose 15-minute test which distinguishes between a bacterial or viral infection is currently being trialled by the NHS.
Who We Are
MeMed is a global leader in host-immune response diagnostics. Our mission is to translate the immune system’s complex signals into simple, actionable insights that empower clinicians to make better infection-management decisions, helping to safeguard antibiotics for future generations.
What We Do
Our flagship test, MeMed BV®, is the first FDA-cleared and CE-marked host-response test that accurately distinguishes bacterial from viral infections in just 15 minutes. By decoding a patient’s immune response, MeMed BV supports timely, evidence-based clinical decisions, ensuring antibiotics are prescribed only when truly needed and reducing unnecessary hospitalisation’s and repeat testing.
Beyond BV, MeMed Severity™ (FDA Breakthrough Device Designation) is designed to aid early risk assessment in patients presenting with suspected infection or sepsis, predicting the likelihood of progression to severe outcomes, bringing an additional layer of clinical insight to time-critical care.
Note: MeMed Severity is not cleared for sale in any territory.
Why Healthcare Providers Need Us
Antibiotic misuse often stems from diagnostic uncertainty at the point of care. MeMed BV reduces that uncertainty by providing an objective, accurate test that supports better antibiotic stewardship, fewer unnecessary admissions, and more efficient patient flow.
Hospitals implementing MeMed BV report:
• Improved resource utilisation
• Faster clinical decisions
• Alignment of care with true clinical need
What We Have Achieved
- Extensive clinical validation across dozens of independent studies
• Global adoption: used in 200+ medical institutions and has informed care for 100,000+ patients
• Regulatory milestones: first FDA-cleared host-response test for bacterial vs viral differentiation; CE-marked
• Operational impact: stronger antibiotic stewardship, fewer unnecessary admissions, and enhanced patient flow through faster, evidence-based decisions
What We Need
- Provider partnerships to embed MeMed BV in emergency, urgent care, and outpatient pathways as a cornerstone of antibiotic stewardship
• Health-system and laboratory collaborations to support implementation, training, and real-world impact measurement (e.g., reduction in unnecessary antibiotics, admissions, and retests)
• Distribution partnerships in select geographies to scale access and service
Contact Us
To learn more or discuss a sales or supply partnership, please contact MeMed via your BIVDA partner channel.
